MLI Education

08/23/2026

IMiDs & CELMoDs both hit cereblon, but that doesn't mean they're in the same class. Dr. Rahul Banerjee dives into what sets CELMoDs apart in this episode of our reelCE series on multiple myeloma.

Claim credit & watch the rest of the series at reelCE.com!

08/22/2026

Is your lenalidomide backbone providing your patients with Multiple Myeloma long-term success? Hear what Dr. Adeel Khan has to say in the first episode of our new reelCE series on .

Watch the full series and collect CE credit at reelCE.com

08/17/2026

What if earning CE fit right into your social media feed? Start earning CE credit with our upcoming series on multiple myeloma, featuring Drs. Rahul Banerjee, Adeel Khan, and Saad Usmani - coming soon!

Follow along & stay tuned!

08/04/2026

Basal insulin isn’t the problem - the approach is. If your patients with T2D are above goal, it’s time to refine your strategy.

Save your spot for a live dinner symposium this Sunday at (or join via livestream) & learn strategies to help CDCESs & BC-ADMs personalize insulin, optimize titration & boost adherence 👉mli.link/cdces-reg

Association of Diabetes Care & Education Specialists

07/17/2026

07/04/2026

That's a wrap on - what a week for research! The take home message - multimodal systemic and local therapy is the future for oncological treatment. Expert faculty share their full analyses on our on-demand webinar soon. Join the waitlist: https://mli.link/hh-esmo26

07/04/2026

Dr. Arndt Vogel stopped by yesterday to chat with us about some of the data that he found most exciting at

07/04/2026

Michel P Ducreaux pondered the future of at 's closing remarks on this sunny Saturday morning in Munich - discussing the future for combinations of systemic and local therapies in treatment

07/03/2026

Our time at is quickly coming to an end - many talks have highlighted the importance of evaluating disease burden prior to treatment. Full expert analysis on-demand redeemable for CME credit. Pre-register: https://mli.link/hh-esmo26

07/03/2026

A 4-year update from the CHIEF French Cohort - the longest prospective real-world follow-up of AtezoBev - has confirmed durable benefit with a survival plateau near 29% at 48 months, with some responses enabling conversion to curative-intent treatment!